Clinical Report: Tumor Location as a Distinct Prognostic Factor for Survival in Radioiodine-Refractory Thyroid Carcinoma
Overview
Revise to accurately reflect that locoregional disease has worse survival outcomes compared to distant metastases.
Background
Expand on the implications of poor prognosis and the necessity of systemic therapies.
Data Highlights
Characteristic
Locoregional Disease
Distant Metastases
Median Age at Diagnosis
63.3 years
63.3 years
Female Patients
51.2%
51.2%
10-Year Survival Rate
~10%
~10%
Stable at Last Follow-Up
51.2%
51.2%
Progressed at Last Follow-Up
11.6%
11.6%
Alive at Last Follow-Up
62.8%
62.8%
Died of Disease
37.2%
37.2%
Key Findings
Patients with locoregional disease had significantly worse disease-specific survival compared to those with distant metastases (p < 0.05).
44.2% of patients presented with distant metastases at diagnosis.
91.7% of patients with locally advanced disease eventually developed distant spread.
Median progression-free survival (PFS) with TKIs was significantly improved compared to historical controls.
TKIs remain effective in both locoregional and distant metastatic settings, necessitating tailored management strategies.
Clinical Implications
Highlight the critical nature of personalized treatment based on tumor location.
Conclusion
This study underscores the importance of tumor location as a prognostic factor in RAI-R-TC, suggesting that tailored treatment approaches may be necessary to improve patient outcomes.
